Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
NextGen Jane, Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 4 distinct art units, indicating that prosecution is spread across separate examination assignments and technical groupings.
MCCORMACK, ERIN KATHLEEN is the busiest examiner, with 1 pending matter. The absence of a larger concentration with any one examiner means that counsel may benefit from matter-level review of claim scope, cited art, and procedural posture. Portfolio coordination remains relevant, but the data does not identify a single examiner relationship as the central management issue.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| BICKHAM, DAWN MARIE | 1 | 43.9% | +65.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17772832 | METHODS FOR THE CHARACTERIZATION OF FLUID | BICKHAM, DAWN MARIE | 61d |
| 18014568 | FETAL TROPHOBLAST COMPOSITIONS AND METHODS | SCHUBERG, LAURA J | — |
| 17772829 | METHODS AND SYSTEMS FOR MENSTRUALOME ANALYSIS | GRAY, JESSICA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17772832 | METHODS FOR THE CHARACTERIZATION OF FLUID | BICKHAM, DAWN MARIE | 61d |
| 18014568 | FETAL TROPHOBLAST COMPOSITIONS AND METHODS | SCHUBERG, LAURA J | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1682 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18014568 | FETAL TROPHOBLAST COMPOSITIONS AND METHODS | SCHUBERG, LAURA J | 1631 | §102§103 | Final Rejection | — | Pending | Jan 05, 2023 |
| 17772829 | METHODS AND SYSTEMS FOR MENSTRUALOME ANALYSIS | GRAY, JESSICA | 1682 | §101§112DP | Final Rejection | — | Pending | Apr 28, 2022 |
| 17772832 | METHODS FOR THE CHARACTERIZATION OF FLUID | BICKHAM, DAWN MARIE | 1685 | §101§103 | Non-Final OA | 61d | Pending | Apr 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNextGen Jane, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Laura J Schuberg has the most, with 1 of NextGen Jane, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
